Eupraxia Pharmaceuticals Files 6-K for 2025 Annual Report
Ticker: EPRX · Form: 6-K · Filed: May 5, 2025 · CIK: 1581178
| Field | Detail |
|---|---|
| Company | Eupraxia Pharmaceuticals Inc. (EPRX) |
| Form Type | 6-K |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, compliance, foreign-private-issuer
TL;DR
Eupraxia Pharma filed its 6-K, submitting its 2025 annual report (Form 40-F).
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on May 5, 2025, indicating it is submitting its annual report under cover of Form 40-F. The company, located in Victoria, British Columbia, Canada, operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing signals the company's compliance with reporting requirements for its annual financial disclosures, providing investors with updated information.
Risk Assessment
Risk Level: low — This is a routine administrative filing for an annual report, not indicating new material events or financial distress.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Registrant
- 001-41923 (company) — Commission File Number
- 201-2067 Cadboro Bay Rd. (company) — Business Address
- Victoria, British Columbia, Canada (company) — Location
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report that Eupraxia Pharmaceuticals Inc. is submitting its annual report under cover of Form 40-F.
When was this Form 6-K filed?
This Form 6-K was filed on May 5, 2025.
What is Eupraxia Pharmaceuticals Inc.'s primary business sector?
Eupraxia Pharmaceuticals Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
Where is Eupraxia Pharmaceuticals Inc. located?
Eupraxia Pharmaceuticals Inc. is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Which form is Eupraxia Pharmaceuticals Inc. using to submit its annual report?
Eupraxia Pharmaceuticals Inc. is submitting its annual report under cover of Form 40-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 5, 2025 regarding EUPRAXIA PHARMACEUTICALS INC. (EPRX).